Black Rock Inc. Clearside Biomedical, Inc. Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
A detailed history of Black Rock Inc. transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 798,137 shares of CLSD stock, worth $742,267. This represents 0.0% of its overall portfolio holdings.
Number of Shares
798,137
Previous 758,226
5.26%
Holding current value
$742,267
Previous $1.16 Million
10.6%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding CLSD
# of Institutions
55Shares Held
12.2MCall Options Held
54.7KPut Options Held
50.7K-
Vanguard Group Inc Valley Forge, PA2.84MShares$2.64 Million0.0% of portfolio
-
Act Capital Management, LLC Wayne, PA2.2MShares$2.04 Million3.43% of portfolio
-
Carmignac Gestion Paris, I01.93MShares$1.8 Million0.04% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny745KShares$692,7460.0% of portfolio
-
Geode Capital Management, LLC Boston, MA731KShares$680,1880.0% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $56M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...